Key facts
- Antheia’s last known valuation is $240.0M (Jun 2021).
- It has raised $176.2M across 5 recorded rounds; the latest was Later Stage VC (Series C) ($80.0M) in Jan 2026.
- Notable investors include US National Science Foundation, Viking Global Investors, National Institutes of Health, In-Q-Tel, Western Technology Investment — 23 tracked in total.
- Antheia has filed 3 Form Ds with the SEC since 2015, most recently Sep 2018 ($9.2M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Antheia
Funding rounds
5 roundsAbout Antheia
Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-based medicines are made using synthetic biology, informatics, and fermentation technology to harness beneficial molecules from plants to create active pharmaceutical ingredients, enabling healthcare organizations to provide patients with natural and healthier medication.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2013
- Employees
- 65
- Website
- antheia.bio/
- Ownership
- Privately Held (backing)
Antheia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antheia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antheia in its N-PORT filings yet. We sweep new filings monthly.